Q4 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Equities research analysts at Leerink Partnrs boosted their Q4 2025 earnings per share estimates for Illumina in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the life sciences company will post earnings of $1.27 per share for the quarter, up from their prior forecast of $1.24. The consensus estimate for Illumina’s current full-year earnings is $4.13 per share. Leerink Partnrs also issued estimates for Illumina’s FY2026 earnings at $5.15 EPS.

Other analysts have also recently issued reports about the company. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a report on Thursday, October 17th. Robert W. Baird raised their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Royal Bank of Canada upped their target price on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. raised their price target on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Piper Sandler dropped their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $165.63.

Illumina Trading Up 1.1 %

Shares of ILMN opened at $136.22 on Thursday. The stock’s fifty day simple moving average is $138.91 and its 200-day simple moving average is $134.26. The firm has a market capitalization of $21.60 billion, a PE ratio of -13.68 and a beta of 1.11. Illumina has a 12-month low of $100.08 and a 12-month high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same period in the previous year, the firm posted $0.33 earnings per share. The company’s revenue was down 3.5% on a year-over-year basis.

Hedge Funds Weigh In On Illumina

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Zacks Investment Management bought a new stake in shares of Illumina in the third quarter valued at about $2,924,000. Freemont Management S.A. acquired a new stake in Illumina in the 3rd quarter valued at approximately $1,565,000. Weybosset Research & Management LLC lifted its stake in Illumina by 92.0% in the 3rd quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock valued at $2,354,000 after acquiring an additional 8,650 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Illumina by 5.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 42,748 shares of the life sciences company’s stock valued at $5,712,000 after purchasing an additional 2,338 shares during the last quarter. Finally, CCLA Investment Management lifted its position in shares of Illumina by 20.5% in the fourth quarter. CCLA Investment Management now owns 535,050 shares of the life sciences company’s stock worth $71,493,000 after purchasing an additional 91,122 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.